Research progress on restenosis after cerebral vascular stenting

doi:10.3877/cma.j.issn.2095-9141.2024.03.009

Abstract

Abstract:

In order to prevent and treat ischemic stroke, active treatment of intracranial and extracranial artery stenosis has become a clinical consensus. In China, endovascular interventional therapy is one of the main treatment methods for intracranial and extracranial artery stenosis, but its safety and effectiveness has always been controversial, one of which is the occurrence of in-stent restenosis (ISR) after intracranial vascular stenting. This paper reviews the incidence, etiology, prediction methods and progress of prevention and treatment of ISR after cerebral vascular stenting, in order to improve clinicians' understanding of ISR and provide reference for reducing the incidence of ISR in clinical work.

Key words: In-stent restenosis, Ischemic stroke, Cerebral vascular stenting, Intracranial and extracranial artery stenosis, Interventional therapy

Jinshuo Yang, Qiaowei Wu, Chunlei Wang, Huaizhang Shi. Research progress on restenosis after cerebral vascular stenting[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2024, 10(03): 174-179.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2024.03.009

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2024/V10/I03/174

References 51

[1]	Chen J, Zhu Q, Yu L, et al. Stroke risk factors of stroke patients in China: a nationwide community-based cross-sectional study[J]. Int J Environ Res Public Health, 2022, 19(8): 4807. DOI: 10.3390/ijerph19084807.
[2]	Wong LK. Global burden of intracranial atherosclerosis[J]. Int J Stroke, 2006, 1(3): 158-159. DOI: 10.1111/j.1747-4949.2006.00045.x.
[3]	Qureshi AI, Caplan LR. Intracranial atherosclerosis[J]. Lancet, 2014, 383(9921): 984-998. DOI: 10.1016/S0140-6736(13)61088-0.
[4]	Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial[J]. Lancet, 2014, 383(9914): 333-341. DOI: 10.1016/S0140-6736(13)62038-3.
[5]	Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial[J]. JAMA, 2015, 313(12): 1240-1248. DOI: 10.1001/jama.2015.1693.
[6]	Gao P, Wang T, Wang D, et al. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: the CASSISS randomized clinical trial[J]. JAMA, 2022, 328(6): 534-542. DOI: 10.1001/jama.2022.12000.
[7]	Yang L, Du H, Zhang D, et al. Complications and long-term in-stent restenosis of endovascular treatment of severe symptomatic intracranial atherosclerotic stenosis and relevant risk factors[J]. Medicine (Baltimore), 2023, 102(38): e34697. DOI: 10.1097/MD.0000000000034697.
[8]	Wang N, Lu Y, Feng L, et al. Identifying risk factors for in-stent restenosis in symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis[J]. Front Neurol, 2023, 14: 1170110. DOI: 10.3389/fneur.2023.1170110.
[9]	Peng G, Zhang Y, Miao Z. Incidence and risk factors of in-stent restenosis for symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis[J]. AJNR Am J Neuroradiol, 2020, 41(8): 1447-1452. DOI: 10.3174/ajnr.A6689.
[10]	Yoon NK, Awad AW, Kalani MY, et al. Stent technology in ischemic stroke[J]. Neurosurg Focus, 2017, 42(4): E11. DOI: 10.3171/2017.1.
[11]	Derdeyn CP, Fiorella D, Lynn MJ, et al. Nonprocedural symptomatic infarction and in-stent restenosis after intracranial angioplasty and stenting in the SAMMPRIS trial (stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis)[J]. Stroke, 2017, 48(6): 1501-1506. DOI: 10.1161/STROKEAHA.116.014537.
[12]	Wang N, Lu Y, Feng L, et al. Identifying risk factors for in-stent restenosis in symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis[J]. Front Neurol, 2023, 14: 1170110. DOI: 10.3389/fneur.2023.1170110.
[13]	Ronchey S, Praquin B, Orrico M, et al. Outcomes of 1000 carotid wallstent implantations: single-center experience[J]. J Endovasc Ther, 2016, 23(2): 267-274. DOI: 10.1177/1526602815626558.
[14]	Chen W, Huang F, Li M, et al. Incidence and predictors of the in-stent restenosis after vertebral artery ostium stenting[J]. J Stroke Cerebrovasc Dis, 27(11): 3030-3035. DOI: 10.1016/j.jstrokecerebrovasdis.2018.06.031.
[15]	Zheng D, Mingyue Z, Wei S, et al. The incidence and risk factors of in-stent restenosis for vertebrobasilar artery stenting[J]. World Neurosurg, 2018, 110: e937-e941. DOI: 10.1016/j.wneu.2017.11.112.
[16]	Alexander MJ, Zauner A, Gupta R, et al. The WOVEN trial: wingspan one-year vascular events and neurologic outcomes[J]. J Neurointerv Surg, 2021, 13(4): 307-310. DOI: 10.1136/neurintsurg-2020-016208.
[17]	Yang K, Fang S, Zhang X, et al. In-stent restenosis after vertebral artery origin stenosis stenting: a nomogram for risk assessment[J]. J Neurointerv Surg, 2023, 15(e1): e41-e45. DOI: 10.1136/neurintsurg-2022-019091.
[18]	龙树海,余笋,时程程,等. Neuroform EZ支架与Enterprise 2代支架在症状性颅内动脉粥样硬化性狭窄治疗中的临床应用对比[J].中华神经医学杂志, 2023, 22(1): 27-36. DOI: 10.3760/cma.j.cn115354-20221010-00701.
[19]	Takao N, Hagiwara Y, Shimizu T, et al. Preprocedural carotid plaque echolucency as a predictor of in-stent intimal restenosis after carotid artery stenting[J]. J Stroke Cerebrovasc Dis, 2020, 29(12): 105339. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105339.
[20]	Cyr AR, Huckaby LV, Shiva SS, et al. Nitric oxide and endothelial dysfunction[J]. Crit Care Clin, 2020, 36(2): 307-321. DOI: 10.1016/j.ccc.2019.12.009.
[21]	Tsuji Y, Koide M, Katsura K, et al. In-stent restenosis with "inflammatory" neointima following everolimus-eluting stent implantation[J]. Int Heart J, 2018, 59(5): 1142-1145. DOI: 10.1536/ihj.17-602.
[22]	Yu Y, Yan L, Lou Y, et al. Multiple predictors of in-stent restenosis after stent implantation in symptomatic intracranial atherosclerotic stenosis[J]. J Neurosurg, 2022, 136(6): 1716-1725. DOI: 10.3171/2021.6.Jns211201.
[23]	Shen J, Song JB, Fan J, et al. Distribution and dynamic changes in matrix metalloproteinase (MMP)-2, MMP-9, and collagen in an in stent restenosis process[J]. Eur J Vasc Endovasc Surg, 2021, 61(4): 648-655. DOI: 10.1016/j.ejvs.2020.11.035.
[24]	Yan LL, Wei XH, Shi QP, et al. Cardiotonic pills® protects from myocardial fibrosis caused by in stent restenosis in miniature pigs[J]. Phytomedicine, 2022, 106: 154405. DOI: 10.1016/j.phymed.2022.154405.
[25]	Liu JP, Wang YZ, Li YK, et al. Matrix metalloproteinase 9 level as an indicator for restenosis following cervical and intracranial angioplasty and stenting[J]. Neural Regen Res, 2015, 10(4): 631-635. DOI: 10.4103/1673-5374.155439.
[26]	Gutierrez-Carretero E, Mayoral-González I, Jesús Morón F, et al. miR-30b-5p downregulation as a predictive biomarker of coronary in-stent restenosis[J]. Biomedicines, 2021, 9(4): 354. DOI: 10.3390/biomedicines9040354.
[27]	Haidegger M, Kneihsl M, Niederkorn K, et al. Blood biomarkers of progressive atherosclerosis and restenosis after stenting of symptomatic intracranial artery stenosis[J]. Sci Rep, 2021, 11(1): 15599. DOI: 10.1038/s41598-021-95135-y.
[28]	Tian B, Zhu C, Tian X, et al. Baseline vessel wall magnetic resonance imaging characteristics associated with in-stent restenosis for intracranial atherosclerotic stenosis[J]. J Neurointerv Surg, 2023, 15(3): 288-291. DOI: 10.1136/neurintsurg-2021-018473.
[29]	Yang WJ, Fisher M, Zheng L, et al. Histological characteristics of intracranial atherosclerosis in a Chinese population: a postmortem study[J]. Front Neurol, 2017, 8: 488. DOI: 10.3389/fneur.2017.00488.
[30]	de Donato G, Pasqui E, Alba G, et al. Clinical considerations and recommendations for OCT-guided carotid artery stenting[J]. Expert Rev Cardiovasc Ther, 2020, 18(4): 219-229. DOI: 10.1080/14779072.2020.1756777.
[31]	Feng Y, Dmytriw AA, Yang B, et al. Neovascularization in human intracranial atherosclerotic in-stent restenosis[J]. Diagnostics (Basel), 2021, 11(2): 322. DOI: 10.3390/diagnostics11020322.
[32]	Liu H, Liu Y, Ip BYM, et al. Effects of stent shape on focal hemodynamics in intracranial atherosclerotic stenosis: a simulation study with computational fluid dynamics modeling[J]. Front Neurol, 2022, 13: 1067566. DOI: 10.3389/fneur.2022.1067566.
[33]	Texakalidis P, Tzoumas A, Giannopoulos S, et al. Risk factors for restenosis after carotid revascularization: a meta-analysis of hazard ratios[J]. World Neurosurg, 2019, 125: 414-424. DOI: 10.1016/j.wneu.2019.02.065.
[34]	Vanags LZ, Wong NKP, Nicholls SJ, et al. High-density lipoproteins and apolipoprotein A-I improve stent biocompatibility[J]. Arterioscler Thromb Vasc Biol, 2018, 38(8): 1691-1701. DOI: 10.1161/atvbaha.118.310788.
[35]	Turan TN, Nizam A, Lynn MJ, et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial[J]. Neurology, 2017, 88(4): 379-385. DOI: 10.1212/wnl.0000000000003534.
[36]	Huang X, Wang X, Zou Y, et al. Impact of cigarette smoking and smoking cessation on stent changes as determined by optical coherence tomography after sirolimus stent implantation[J]. Am J Cardiol, 2017, 120(8): 1279-1284. DOI: 10.1016/j.amjcard.2017.07.011.
[37]	Anjorin AC, Marcaccio CL, Rastogi V, et al. Statin therapy is associated with improved perioperative outcomes and long-term mortality following carotid revascularization in the vascular quality initiative[J]. J Vasc Surg, 2023, 77(1): 158-169.e8. DOI: 10.1016/j.jvs.2022.08.019.
[38]	Kang Z, Cao Y, Li L, et al. The association between apolipoprotein E gene polymorphism and in-stent restenosis after extracranial and intracranial artery stenting[J]. J Stroke Cerebrovasc Dis, 2021, 30(1): 105424. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105424.
[39]	Zhang M, Wang J, Zhang Y, et al. Impacts of CYP2C19 polymorphism and clopidogrel dosing on in-stent restenosis: a retrospective cohort study in Chinese patients[J]. Drug Des Devel Ther, 2020, 14: 669-676. DOI: 10.2147/dddt.S242167.
[40]	Qiao H, Chang CH, Wang AY, et al. Safety and efficacy of drug coated balloon angioplasty for intracranial atherosclerotic disease[J]. J Neurointerv Surg, 2023, 15(e2): e172-e177. DOI: 10.1136/jnis-2022-019122.
[41]	Jia B, Zhang X, Ma N, et al. Comparison of drug-eluting stent with bare-metal stent in patients with symptomatic high-grade intracranial atherosclerotic stenosis: a randomized clinical trial[J]. JAMA Neurol, 2022, 79(2): 176-184. DOI: 10.1001/jamaneurol.2021.4804.
[42]	Ma X, Jiang C, Li Y, et al. Inhibition effect of tacrolimus and platelet-derived growth factor-BB on restenosis after vascular intimal injury[J]. Biomed Pharmacother, 2017, 93: 180-189. DOI: 10.1016/j.biopha.2017.06.027.
[43]	Guo X, Ma N, Gao F, et al. Long-term risk factors for intracranial in-stent restenosis from a multicenter trial of stenting for symptomatic intracranial artery stenosis registry in China[J]. Front Neurol, 2020, 11: 601199. DOI: 10.3389/fneur.2020.601199.
[44]	Zhang K, Li TX, Wang ZL, et al. Factors affecting in-stent restenosis after angioplasty with the enterprise stent for intracranial atherosclerotic diseases[J]. Sci Rep, 2021, 11(1): 10479. DOI: 10.1038/s41598-021-89670-x.
[45]	Park SC, Cho SH, Kim MK, et al. Long-term outcome of angioplasty using a wingspan stent, post-stent balloon dilation and aggressive restenosis management for intracranial arterial stenosis[J]. Clin Neuroradiol, 2020, 30(1): 159-169. DOI: 10.1007/s00062-019-00793-1.
[46]	中国卒中学会神经介入分会.症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识2022[J].中国卒中杂志, 2022, 17(8): 863-888. DOI: 10.3969/j.issn.1673-5765.2022.08.013.
[47]	Ye G, Yin X, Yang X, et al. Efficacy and safety of drug-eluting stent for the intracranial atherosclerotic disease: a systematic review and meta-analysis[J]. J Clin Neurosci, 2019, 59: 112-118. DOI: 10.1016/j.jocn.2018.10.118.
[48]	Guo Z, Liu C, Huang K, et al. Meta-analysis of redo stenting versus endarterectomy for in-stent stenosis after carotid artery stenting[J]. J Vasc Surg, 2021, 73(4): 1282-1289. DOI: 10.1016/j.jvs.2020.07.102.
[49]	周帅,王海波,刘朋飞,等.症状性椎动脉起始部重度狭窄/闭塞行椎动脉内膜切除术的疗效分析[J].中华神经创伤外科电子杂志, 2023, 9(3): 170-174. DOI: 10.3877/cma.j.issn.2095-9141.2023.03.008.
[50]	Yazdani SK, Lei B, Cawthon CV, et al. Local intraluminal delivery of a smooth muscle-targeted RNA ligand inhibits neointima growth in a porcine model of peripheral vascular disease[J]. Mol Ther Nucleic Acids, 2022, 29: 577-583. DOI: 10.1016/j.omtn.2022.08.007.
[51]	Zhu J, Liu B, Wang Z, et al. Exosomes from nicotine-stimulated macrophages accelerate atherosclerosis through miR-21-3p/PTEN-mediated VSMC migration and proliferation[J]. Theranostics, 2019, 9(23): 6901-6919. DOI: 10.7150/thno.37357.

Please choose a citation manager

Content to export